Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia

References

• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heinonen K, Bloomfield CD. Prognostic value of cytogenetic findings in adults with acute myeloid leukemia. Int J Hematol. 2000;72:261–271.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cortes J, Estrov Z, et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. JCO. 2011;29:2507–2513.
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–433.
   PubMed Web of Science ®Google Scholar
• Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314:811–822.
   PubMed Web of Science ®Google Scholar
• Paietta E. Should minimal residual disease guide therapy in AML? Best Pract Res Clin Haematol. 2015;28:98–105.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Saini L, Brandwein J, Turner R, et al. Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. Leuk Res. 2016;45:47–52.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Stuart-Smith SE, Bain BJ. How should stainable iron in bone marrow films be assessed? J Clin Pathol. 2004;57:1038–1040.
   PubMed Web of Science ®Google Scholar
• Lee SH, Erber WN, Porwit A, et al. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30:349–364.
   PubMed Web of Science ®Google Scholar
• Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior Iliac crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol. 1965;43:326–331.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. JCO. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Ayala F, Dewar R, Kieran M, et al. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia. 2009;23:2233–2241.
   PubMed Web of Science ®Google Scholar
• Dvorakova M, Karafiat V, Pajer P, et al. DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment. Oncogene. 2013;32:5201–5209.
   PubMed Web of Science ®Google Scholar
• Geyh S, Rodriguez-Paredes M, Jager P, et al. Functional inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia. 2016;30:683–691.
   PubMed Web of Science ®Google Scholar
• Chandran P, Le Y, Li Y, et al. Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leuk Res. 2015;39:486–493.
   PubMed Web of Science ®Google Scholar
• Martens AC, Schultz FW, Hagenbeek A. Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood. 1987;70:1073–1078.
   PubMed Web of Science ®Google Scholar
• Vanderhoek M, Juckett MB, Perlman SB, et al. Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging. Leuk Res. 2011;35:310–316.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Cassileth PA, Head DR, et al. Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. JCO. 1990;8:813–819.
   PubMed Web of Science ®Google Scholar
• Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. JCO. 2015;33:1258–1264.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Oliver F, et al. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Bone Marrow Transplant. 1997;19:1117–1123.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrozek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. JCO. 2004;22:2410–2418.
   PubMed Web of Science ®Google Scholar
• Oran B, Popat U, Rondon G, et al. Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013;19:214–220.
   PubMed Web of Science ®Google Scholar